Office of Regulatory Management

Economic Review Form

Agency name	Board of Pharmacy
Virginia Administrative	18VAC110-30
Code (VAC) Chapter	
citation(s)	
VAC Chapter title(s)	Regulations for Practitioners of the Healing Arts to Sell Controlled Substances
A 4. 4.1	I1
Action title	Implementation of 2021 Periodic Review
Date this document	4/18/2023
prepared	
Regulatory Stage	Proposed
(including Issuance of	
Guidance Documents)	

Cost Benefit Analysis

Complete Tables 1a and 1b for all regulatory actions. You do not need to complete Table 1c if the regulatory action is required by state statute or federal statute or regulation and leaves no discretion in its implementation.

Table 1a should provide analysis for the regulatory approach you are taking. Table 1b should provide analysis for the approach of leaving the current regulations intact (i.e., no further change is implemented). Table 1c should provide analysis for at least one alternative approach. You should not limit yourself to one alternative, however, and can add additional charts as needed.

Report both direct and indirect costs and benefits that can be monetized in Boxes 1 and 2. Report direct and indirect costs and benefits that cannot be monetized in Box 4. See the ORM Regulatory Economic Analysis Manual for additional guidance.

Table 1a: Costs and Benefits of the Proposed Changes (Primary Option)

(1) Direct & Indirect Costs & Benefits (Monetized)	There are no direct costs related to these changes. It is possible that there is an indirect cost to require a licensee of the healing arts to lease or purchase an appropriate facility to receive a permit to dispense medication, but prescription medications cannot be legally secured in a home as required by existing federal law, so this is arguably an existing cost. There are no benefits or indirect benefits from these changes.			
(2) Present				
Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits		
	(a) 0	(b) 0		
(3) Net Monetized Benefit	0			
(4) Other Costs &	0			
Benefits (Non-				
Monetized)				
(5) Information				
Sources				

Table 1b: Costs and Benefits under the Status Quo (No change to the regulation)

(1) Direct & Indirect Costs & Benefits (Monetized)	There are no direct or indirect costs to status quo. No direct or indirect benefits to status quo.		
(2) Present			
Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits	
	(a) (b)		
(3) Net Monetized			
Benefit			
(4) Other Costs &			
Benefits (Non-			
Monetized)			

Sources			
Table 1c: Costs and	Benefits under Alternative	e Approac	ch(es)
(1) Direct & Indirect Costs & Benefits (Monetized)	There are no alternative approaches to these changes. Regulatory amendment is required to implement the changes.		
(2) Present Monetized Values	Direct & Indirect Costs	Direct	& Indirect Benefits
	(a)	(b)	
(3) Net Monetized Benefit			
(4) Other Costs & Benefits (Non- Monetized)			
(5) Information Sources			
Impact on Local Pa		G. D.	
	eribe impacts on local partner or additional guidance.	rs. See Pa	rt 8 of the ORM Cost Impact
Table 2: Impact on	Local Partners		
(1) Direct & Indirect Costs & Benefits (Monetized)	There is no impact on loca	l partners.	
(2) Present Monetized Values	Direct & Indirect Costs		Direct & Indirect Benefits

(5) Information

(a)

(3) Other Costs & Benefits (Non-Monetized) (b)

(4) Assistance	
(5) Information Sources	

Impacts on Families

Use this chart to describe impacts on families. See Part 8 of the ORM Cost Impact Analysis Guidance for additional guidance.

Table 3: Impact on Families

Table 3. Impact on	i annies	
(1) Direct &	There is no impact on families	•
Indirect Costs &		
Benefits		
(Monetized)		
(2) Present		
` /		
Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits
	(a)	(b)
(2) (24) C 0	<u> </u>	
(3) Other Costs &		
Benefits (Non-		
`		
Monetized)		
(4) Information		
Sources		
2041005		

Impacts on Small Businesses

Use this chart to describe impacts on small businesses. See Part 8 of the ORM Cost Impact Analysis Guidance for additional guidance.

Table 4: Impact on Small Businesses

(1) Direct & Indirect Costs & Benefits (Monetized)	There is no impact on small businesses. Although some small businesses may need to lease or purchase operating space as described in Table 1, those businesses would have needed to do so to comply with existing federal requirements.		
(2) Present Monetized Values	Direct & Indirect Costs (a) Direct & Indirect Benefits (b)		

(3) Other Costs & Benefits (Non- Monetized)	
(4) Alternatives	
(5) Information Sources	

Changes to Number of Regulatory Requirements

Table 5: Regulatory Reduction

For each individual action, please fill out the appropriate chart to reflect any change in regulatory requirements, costs, regulatory stringency, or the overall length of any guidance documents.

Change in Regulatory Requirements

VAC Section(s) Involved	Initial Count	Additions	Subtractions	Net Change
18VAC110-30- 21	8	1	0	+1
18VAC110-30- 55	0	3	0	+3
18VAC110-30- 80	7	1	0	+1

Cost Reductions or Increases (if applicable)

VAC Section(s) Involved	Description of Regulatory Requirement	Initial Cost	New Cost	Overall Cost Savings/Increases

Other Decreases or Increases in Regulatory Stringency (if applicable)

VAC Section(s) Involved	Description of Regulatory Change	Overview of How It Reduces or Increases Regulatory Burden

Length of Guidance Documents (only applicable if guidance document is being revised)

	, , , , , , ,	<i>v</i>	<u> </u>
Title of Guidance	Original Length	New Length	Net Change in
Document			Length